Microbiology & Virology Market Research Reports & Industry Analysis
One of the main focuses in virology is the study of viral infectious diseases including: rhinoviruses (common cold), influenza (flu), Herpes (simplex, zoster and varicella-zoster), AIDS (autoimmune deficiency virus), Human Papillomavirus (HPV), rabies and measles.
Some viruses, known as oncoviruses, are known to be cancer causing. The most widely studied example is the link between HPV, a sexually transmitted virus, and cervical cancer.
There are more then 150 strains of HPV, over 40 of which are sexually transmitted. Certain types of “high-risk” sexually transmitted HPV viruses can lead to cell mutations and cause cervical cancer as well as cancer of the vagina, vulva, penis and anus. Research shows that these high-risk HPV viruses cause over 99% of cervical cancers.
According to the National Cancer Institute, it is estimated that in 2010 about 12,000 women in the United States were diagnosed with cervical cancer and more than 4000 would die from it.
Although there are no treatments available for HPV, the FDA approved Cervarix and Gardisil, vaccines used to protect against the types of HPV that most commonly cause cervical cancer.
Microbiology & Virology Industry Research & Market Reports
-
Saudi Arabia In-Vitro Diagnostics (IVD) Market (By Segment, Application, Product, End User), Size, Share, Major Deals, Key Company Profiles, Revenue, Recent Developments - Forecast to 2030
... in other countries, Saudi Arabia is facing the challenges of fighting with infectious disease including HBV, TB, HCV and HIV, as well as various chronic diseases and cancer. In-vitro diagnostics plays an important role in ... Read More
-
Viral Hepatitis and Retrovirus Diagnostic Tests
... reach US$7.7 Billion by 2030, growing at a CAGR of 8.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 11.3% CAGR The Viral ... Read More
-
Women`s Health Diagnostics
... at a CAGR of 5.8% over the analysis period 2024-2030. Breast Cancer Testing, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$11.3 Billion by the end ... Read More
-
Zika Virus Testing
... at a CAGR of 5.8% over the analysis period 2024-2030. Molecular Testing, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$192.4 Million by the end of ... Read More
-
Chlamydia Infection Diagnostics and Therapeutics
... Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Diagnostics, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$1.6 Billion by ... Read More
-
Legionella Testing
... CAGR of 8.2% over the analysis period 2024-2030. Culture Methods, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$122.4 Million by the end of the analysis ... Read More
-
Herpes Marker Testing
... at a CAGR of 4.9% over the analysis period 2024-2030. Antibody / Antigen-Based Kits, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$332.9 Million by the ... Read More
-
Industrial Microbiology
... CAGR of 4.6% over the analysis period 2024-2030. Pharmaceuticals, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$11.6 Billion by the end of the analysis period. ... Read More
-
Pneumonia Testing
... CAGR of 6.2% over the analysis period 2024-2030. Immunodiagnostics, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$339.9 Million by the end of the analysis period. ... Read More
-
Poultry Diagnostics
... CAGR of 9.0% over the analysis period 2024-2030. ELISA, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$558.3 Million by the end of the analysis period. ... Read More
-
Automated and Rapid Microbiological Tests
... Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. GC/CRT (Clinical), one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$1.3 Billion ... Read More
-
Human Papillomavirus (HPV) Testing
... 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Hospitals & Clinics, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$919.4 Million by ... Read More
-
Immunoprotein Diagnostic Testing
... at a CAGR of 5.2% over the analysis period 2024-2030. Immunoglobulin Diagnostic, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$6.4 Billion by the end of ... Read More
-
Mycoplasma Testing
... CAGR of 8.6% over the analysis period 2024-2030. Assays, Kits & Reagents, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$940.8 Million by the end of ... Read More
-
Critical Care Diagnostics
... at a CAGR of 5.9% over the analysis period 2024-2030. Immunoproteins, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$713.5 Million by the end of the ... Read More
-
Dengue Testing
... CAGR of 4.8% over the analysis period 2024-2030. Hospitals, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$367.8 Million by the end of the analysis period. ... Read More
-
Sepsis Diagnostics
... CAGR of 7.5% over the analysis period 2024-2030. Microbiology, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$749.8 Million by the end of the analysis period. ... Read More
-
Microbiology Culture
... CAGR of 3.8% over the analysis period 2024-2030. Eukaryotic Culture, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$5.2 Billion by the end of the analysis ... Read More
-
Cervical Cancer Diagnostic Testing
... 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Pap Smear, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$5.3 Billion by the ... Read More
-
STD Testing
... CAGR of 5.2% over the analysis period 2024-2030. Chlamydia, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$40.6 Billion by the end of the analysis period. ... Read More
-
Tuberculosis Testing
... CAGR of 4.9% over the analysis period 2024-2030. Hospitals, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.4 Billion by the end of the analysis period. ... Read More
-
Enteric Disease Testing
... at a CAGR of 4.9% over the analysis period 2024-2030. Bacterial Enteric Disease, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$1.8 Billion by the end ... Read More
-
Clinical Microbiology Instruments and Reagents
... Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$2.4 Billion by ... Read More
-
Clostridium Diagnostics
... CAGR of 14.2% over the analysis period 2024-2030. Immunoassays, one of the segments analyzed in the report, is expected to record a 15.6% CAGR and reach US$9.1 Billion by the end of the analysis period. ... Read More
-
Medical Microbiology Testing Technologies
... 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Respiratory Diseases, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$1.4 Billion by the ... Read More
Research Assistance
